Empowering cancer immunotherapy
Cancer. Personalized.
Our Mission
Our vision is to become an industry leader in the development of new cancer immunotherapies that safely and effectively reawaken the body's immune system to recognize, seek out, and destroy tumors to provide patients with a lasting treatment option personalized to their particular cancer. Our company's identity is built on a foundation of core values that prioritize trust, transparency, and devotion to translating excellent science into improved outcomes for the patients we aim to serve.
Our Science
With decades of combined experience in multidisciplinary fields spanning immunology, cancer immunotherapy, bacterial genetics, and cell and molecular biology, our team has developed a cutting edge molecular delivery platform based on recombinant bacterial minicells (rBMCs). We have leveraged our platform to produce VAX014, a first-in-class non-viral tumor-targeted oncolytic immunotherapy agent now undergoing early stage clinical trials.
Our CLINICAL TRIALS
Our lead immunotherapy product VAX014 is currently being evaluated as an intratumoral immunotherapy in patients with advanced solid tumors that are resistant to approved treatment options. VAX014 has also been evaluated for the treatment of non-muscle invasive bladder cancer.